Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Automatically detect candlestick patterns on any chart

Indivior Pharmaceuticals Inc.

Contributing Author

Recent Articles by Indivior Pharmaceuticals Inc.

Aug-03	Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance INDV -6.60% GlobeNewswire
Jul-23	Indivior to Report Second Quarter 2026 Financial Results and Host Webcast INDV GlobeNewswire
May-20	New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization INDV GlobeNewswire
May-14	Indivior to Participate in Upcoming Investor Conferences INDV GlobeNewswire
May-04	Indivior Announces $175 Million Accelerated Share Repurchase INDV GlobeNewswire
Apr-30	Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance INDV +7.70% GlobeNewswire
Apr-24	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder INDV GlobeNewswire
Apr-16	Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse INDV GlobeNewswire
Apr-09	Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th INDV GlobeNewswire
Mar-31	New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities INDV +5.91% GlobeNewswire
Mar-17	National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder INDV GlobeNewswire
Mar-12	Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering INDV GlobeNewswire
Mar-12	Indivior Announces Proposed Convertible Senior Notes Offering INDV -6.00% GlobeNewswire
Mar-11	New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder INDV GlobeNewswire
Feb-26	Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results INDV GlobeNewswire
Feb-24	Indivior to Participate in Upcoming Investor Conferences INDV GlobeNewswire
Jan-28	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ INDV GlobeNewswire
Jan-26	Indivior Announces Completion of Redomiciliation to the United States INDV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)